Lung metastases in patients with differentiated thyroid carcinoma and evaluation of response to radioiodine therapy

Revista Espanola de Medicina Nuclear e Imagen Molecular

Volumn 31, Issue 6, 2012, Pages 328-331

  Kalender, E ^a   Zeki Celen, Y ^a   Elboga, U ^a   Deniz Demir, H ^a   Yilmaz, M ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

Differentiated thyroid carcinoma; Lung metastases; Radioiodine therapy

Indexed keywords

IODINE 131; THYROGLOBULIN;

ADULT; ARTICLE; DIFFERENTIATED THYROID CANCER; DRUG MEGADOSE; DRUG UPTAKE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG METASTASIS; LUNG SCINTISCANNING; MAJOR CLINICAL STUDY; MALE; THYROGLOBULIN BLOOD LEVEL; TREATMENT RESPONSE;

ADENOCARCINOMA, FOLLICULAR; ADULT; BONE NEOPLASMS; CARCINOMA, PAPILLARY; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IODINE RADIOISOTOPES; LUNG NEOPLASMS; MALE; PREVALENCE; RADIOPHARMACEUTICALS; REMISSION INDUCTION; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME; WHOLE BODY IMAGING; YOUNG ADULT;

EID: 84867429603     PISSN: 2253654X     EISSN: 22538070     Source Type: Journal    
DOI: 10.1016/j.remn.2012.04.007     Document Type: Article

References (24)

1. Gorges R. The changing epidemiology of thyroid cancer. Thyroid cancer 2001, 3-25. Springer Verlag, Berlin. Biersack H.J., F. Grunwald (Eds.).
2. Golden S.H., Robinson K.A., Saldanha I., Anton B., Ladenson P.W. Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab 2009, 94:1853-1878.
3. Burns W.R., Zeiger M.A. Differentiated thyroid cancer. Semin Oncol 2010, 37:557-566.
4. Sipos J.A., Mazzaferri E.L. Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol) 2010, 22:395-404.
5. Davies L., Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006, 295:2164-2167.
6. Sherman S.I. Thyroid carcinoma. Lancet 2003, 361:501-511.
7. Zettinig G., Fueger B.J., Passler C., Kaserer K., Pirich C., Dudczak R., et al. Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma - surgery or conventional therapy. Clin Endocrinol 2002, 56:377-382.
8. Mazzaferri E.L., Massoll N. Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endocrine-Related Cancer 2002, 9:227-247.
9. Durante C., Haddy N., Baudin E., Leboulleux S., Hartl D., Travagli J.P., et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006, 91:2892-2899.
10. O'Neill C.J., Oucharek J., Learoyd D., Sidhu S.B. Standard and emerging therapies for metastatic differentiated thyroid cancer. Oncologist 2010, 15:146-156.
11. Schlumberger M., Tubiana M., De Vathaire F., Hill C., Gardet P., Travagli J.P., et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1986, 63:960-967.
12. Johnston G., Sweeney D. Differentiated thyroid carcinoma: radioiodine therapy. Thyroid cancer: comprehensive guide to clinical management 2000, 213-220. Humana Press, New Jersey. L. Wartofsky (Ed.).
13. Society of nuclear medicine procedure guideline for therapy of thyroid disease with iodine-131 (sodium iodide); 2002.
14. Dietlein M., Moka D., Schicha H. Radioiodine therapy for thyroid cancer. Thyroid cancer 2001, 91-120. Springer Verlag, Berlin. H.J. Biersack, F. Grünwald (Eds.).
15. Hundahl S., Fleming I.D., Fremgen A.M., Menck H.R. A national cancer database report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer 1998, 82:2638-2648.
16. Gilliland F.D., Hunt W.C., Morris D.M., Key C.R. Prognostic factors for thyroid carcinoma: a population-based study of 15,698 cases for the surveillance, epidemiology and end results (SEER) program 1973-1991. Cancer 1997, 79:564-573.
17. Lin J.D., Chao T.C., Chou S.C., Hsueh C. Papillary thyroid carcinomas with lung metastases. Thyroid 2004, 14:1091-1096.
18. Mazzaferri E.L., Jhiang S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994, 97:418-428.
19. Mazzaferri E.L., Kloos R.T. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001, 86:1447-1463.
20. Shah S.H., Muzaffar S., Soomro I.N., Hasan S.A. Morphological pattern and frequency of thyroid tumors. JPMA: J Pak Med Assoc 1999, 49:131-133.
21. Ezaki H., Ebihara S., Fujimoto Y. Analysis of thyroid carcinoma based on material registered in Japan during 1977-1986 with special reference to predominance of papillary type. Cancer 1992, 15:808-814.
22. Hindié E., Mellière D., Lange F., Hallaj I., de Labriolle-Vaylet C., Jeanguillaume C., et al. Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis. Eur J Nucl Med Mol Imaging 2003, 30:974-981.
23. Ilgan S., Karacalioglu A.O., Pabuscu Y., Atac G.K., Arslan N., Ozturk E., et al. Iodine-131 treatment and high-resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2004, 31:825-830.
24. Schlumberger M., Challeton C., De Vathaire F., Travagli J.P., Gardet P., et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 1996, 37:598-605.